CJC-1295

CJC-1295 as a Muscle Growth & Performance Peptide

CJC-1295 is a synthetic GHRH analogue modified with DAC technology, which prolongs its plasma half-life to approximately 8 days through covalent albumin binding, enabling once-weekly administration in practitioner-reported protocols. It is primarily investigated in research settings involving GH pulse amplification, IGF-1 elevation, support for lean mass, and body composition. Unlike shorter-acting secretagogues, CJC-1295 DAC may remain active for approximately eight days, distinguishing it from both Sermorelin and Modified GRF 1-29 (CJC-1295 without DAC). The compound is not FDA-approved for therapeutic use and remains a research peptide.

CJC-1295 + Ipamorelin: The Combination Protocol

CJC-1295 is most commonly discussed in combination with Ipamorelin because the two peptides act on different receptors involved in endogenous growth hormone release.

• CJC-1295 acts on the GHRH receptor to amplify and prolong GH pulse duration.
• Meanwhile, Ipamorelin acts as a selective agonist at the ghrelin receptor (GHS-R1a), initiating GH pulse release without significant elevations in cortisol or prolactin.

This dual-receptor activation is the mechanistic rationale commonly cited for the combination’s potential to enhance GH pulsatility more effectively than either compound used alone.

Practitioner-reported protocols commonly reference CJC-1295 at 1-2 mg subcutaneously once weekly and Ipamorelin at 100–300 mcg administered two to three times daily or before sleep. In performance-oriented research settings, the combination is discussed in relation to lean mass support, recovery optimization, fat oxidation, and sleep-related recovery benefits.

Evidence for these outcomes remains largely limited to early human data and practitioner-reported observations, and no large-scale human RCTs have directly evaluated the combination.

How CJC-1295 Works: The DAC Mechanism

CJC-1295 binds GHRH receptors on anterior pituitary somatotroph cells, stimulating endogenous GH synthesis and pulsatile release. Once GH enters circulation, hepatic signaling contributes to IGF-1 production, which mediates downstream anabolic, lipolytic, and recovery-related effects.

The DAC modification promotes covalent binding to albumin via lysine residues, creating a depot-like effect that prolongs systemic exposure to approximately eight days after administration, as demonstrated in early human pharmacokinetic data. This duration of action is the primary differentiator from Sermorelin, which has a half-life of approximately 10-20 minutes and typically requires daily administration, and from Tesamorelin, which also has a shorter half-life despite sharing GHRH receptor activity.

Research: dose administration does not appear to suppress endogenous GHRH production to the same extent as exogenous recombinant GH, which may suppress physiologic pulsatility, and practitioner discussions frequently cite the preservation of natural GH architecture as a potential advantage of GHRH analogue-based approaches.

CJC 1295 for Muscle Growth: Clinical Outcomes

All outcomes below should be understood as research-derived, stratified by evidence tier, and not interpreted as established clinical results.

Lean Mass Support

CJC-1295 for muscle growth is primarily associated with IGF-1-mediated anabolic signaling rather than direct activation of muscle receptors. Elevated IGF-1 may support muscle protein synthesis, connective tissue remodeling, and recovery. Studies have demonstrated prolonged increases in GH and IGF-1 following DAC-modified GHRH analogue administration in healthy adults. Practitioner-reported outcomes frequently include improvements in lean body mass and recovery tolerance, though controlled-trial evidence for these specific outcomes remains limited.

Fat Oxidation and Weight Loss

GH signaling is associated with lipolysis and fatty acid mobilization, particularly involving visceral adipose tissue. Some practitioners report reductions in body fat percentage during prolonged protocols, though these effects are considered secondary to GH-mediated metabolic changes rather than direct thermogenic activity. Evidence supporting fat oxidation and weight loss is stronger for GH physiology broadly than for CJC-1295 specifically, and body composition claims remain largely extrapolated from the GHRH analogue class.

Recovery and Sleep Quality

Pre-sleep administration is recommended in practitioner protocols because endogenous nocturnal GH pulses peak naturally during early sleep cycles. Some users report reduced inter-session fatigue and improved restorative sleep, potentially linked to amplified physiologic GH pulsatility. Controlled human evidence evaluating recovery and sleep quality outcomes remains limited, and reported benefits vary significantly between protocols.

Administration of CJC-1295

All dosing information should be treated as practitioner-reported and research-extrapolated. No FDA-validated protocol exists for CJC-1295. 

CJC-1295 DAC is commonly discussed at 1-2 mg administered subcutaneously once weekly. Stable plasma levels may take several weeks to establish, given the peptide’s extended pharmacokinetic profile. Reconstitution is typically performed using bacteriostatic water under sterile conditions, with storage at 2-8°C and protection from direct light exposure thereafter.

Subcutaneous injection sites commonly referenced include the abdomen, thigh, or upper arm. Rotation of injection sites is advised to minimize localized irritation. All administration references require professional oversight and individualized clinical assessment.

Is CJC-1295 Safe? Side Effects & Risk Profile

Safety discussions surrounding CJC-1295 are based on early human studies, practitioner observations, and extrapolation from related GHRH analogues. Long-term randomized controlled trial data are currently lacking.

The most commonly reported side effects following subcutaneous administration include mild water retention, transient edema, and injection-site irritation. These reactions are generally described as short-term and manageable in practitioner literature.

For professionals seeking to buy CJC-1295 online, it is important to review available safety data, product documentation, and supplier quality standards before evaluation. A more significant consideration involves prolonged IGF-1 elevation, particularly in individuals with hormone-sensitive conditions or oncologic histories, as IGF-1 signaling is associated with cellular proliferation pathways. Long-term safety data remain unavailable, and this evidence gap should be communicated clearly in any research or protocol discussion.

CJC-1295 vs Sermorelin, Tesamorelin & Ipamorelin

CJC-1295 is commonly compared with other growth hormone secretagogues because of its DAC-mediated extension of half-life and prolonged activity. Practitioners evaluating whether to purchase CJC-1295 online often compare it with Sermorelin, Tesamorelin, and Ipamorelin to better understand differences in receptor targets, dosing frequency, duration of action, and regulatory status. These distinctions can influence product selection in research-focused and investigational protocols.

CJC-1295 vs Sermorelin

CJC-1295 and Sermorelin are both GHRH analogues, but their pharmacokinetic profiles differ substantially. Sermorelin has a circulating half-life of approximately 10-20 minutes, which typically necessitates daily administration in practitioner-reported protocols. By contrast, DAC-mediated albumin binding allows CJC-1295 to remain active for approximately eight days, supporting once-weekly dosing.

Practitioners evaluating dosing convenience and adherence may favor CJC-1295 when prolonged GH stimulation is the primary research objective, while Sermorelin may be considered when shorter-acting, more titratable GH stimulation is preferred.

CJC-1295 vs Tesamorelin

Tesamorelin is a GHRH analogue with an FDA-approved indication for HIV-associated lipodystrophy, providing it with a stronger regulatory evidence framework in that specific clinical population. Unlike CJC-1295, Tesamorelin has a considerably shorter half-life and targets a distinct therapeutic objective.

CJC-1295 is discussed primarily in performance and body composition research contexts, where prolonged GH stimulation is the goal, whereas Tesamorelin is more relevant in contexts that require an approved therapeutic indication and a defined clinical population.

CJC-1295 vs Ipamorelin

CJC-1295 and Ipamorelin act on entirely different receptor systems and are most accurately described as complementary rather than competing compounds. CJC-1295 activates the GHRH receptor to amplify and sustain GH pulse amplitude, while Ipamorelin stimulates ghrelin receptors to initiate GH pulse release selectively without significant cortisol or prolactin elevation. This receptor differentiation underpins the CJC-1295 and Ipamorelin stacking strategy commonly discussed in practitioner-reported protocols.

Practitioners’ choice between using one compound and using both depends on research objectives, desired GH pulse characteristics, and patient-specific risk assessment.

Legal Status of CJC-1295

Information current as of June 2026. Practitioners should verify current regulatory status in their jurisdiction directly with the relevant authority before sourcing or discussing CJC-1295 in any clinical or research context.

• United States: CJC-1295 is not FDA-approved for therapeutic use and is classified as a research compound. Practitioners should consult current FDA guidance to confirm applicable compounding and research-use restrictions before any sourcing or protocol discussion.
• Australia: CJC-1295 is not TGA-approved, and compounding availability is restricted. Practitioners should verify current TGA status and jurisdiction-specific compounding requirements before any clinical or research discussion.
• WADA: Growth hormone secretagogues are prohibited in competition under WADA category S2, covering peptide hormones and related substances. Practitioners managing competitive athletes should treat CJC-1295 as a prohibited substance and verify its current WADA status using official materials before discussing protocols.

Where Can Practitioners Buy CJC-1295 Online?

CJC-1295 is available for research purposes to qualified professionals only and is not intended for general consumer use. When evaluating suppliers, practitioners should prioritize those that can provide verifiable purity documentation, LOT number traceability, and a current certificate of analysis for each batch. Doctor Medica supports licensed professionals by offering sourcing guidance and access to relevant documentation.

Practitioners looking to buy CJC-1295 wholesale from a verified research-grade supplier are encouraged to contact Doctor Medica’s staff directly for assistance.

FAQs

1. What is CJC 1295?

CJC-1295 is a synthetic GHRH analogue modified with DAC technology to extend plasma half-life to approximately eight days through albumin binding. It is primarily investigated in research settings involving endogenous GH stimulation, IGF-1 elevation, and support for body composition. It is not FDA-approved for therapeutic use.

2. What does CJC 1295 do?

CJC-1295 stimulates GHRH receptors in the anterior pituitary, increasing pulsatile GH release and downstream IGF-1 production. Early human data and practitioner-reported observations associate the compound with support for lean mass, enhanced recovery, and lipolytic activity. Most effects are considered indirect consequences of GH pathway activation.

3. Does CJC-1295 + Ipamorelin work?

CJC-1295 and Ipamorelin are frequently combined because they stimulate different receptors involved in GH regulation. Practitioner-reported protocols suggest additive GH pulse effects via simultaneous activation of GHRH and ghrelin receptors. Large-scale human RCT evidence evaluating combination outcomes remains limited, and findings should be framed as research-derived.

4. What is the CJC-1295 dosage?

Practitioner-reported CJC-1295 DAC protocols commonly reference 1-2 mg administered subcutaneously once weekly. Combination protocols with Ipamorelin often include additional daily or pre-sleep dosing for the second compound. These figures are research-extrapolated and not FDA-validated.

5. Is CJC-1295 safe?

Current safety discussions are based on early human data, practitioner observations, and extrapolation from the GHRH analogue class. Commonly reported side effects include mild water retention, transient edema, and injection-site irritation. Prolonged IGF-1 elevation remains an area requiring further investigation, and long-term RCT data are unavailable.

6. What is the difference between CJC-1295 with and without DAC?

The DAC modification enables albumin binding, extending plasma half-life to approximately eight days. Non-DAC variants, commonly referred to as Modified GRF 1-29, have substantially shorter activity durations and require more frequent dosing. This pharmacokinetic difference is the primary distinction between the two versions.

7. Is CJC-1295 legal?

CJC-1295 is classified as a research compound in the United States and is not FDA-approved for therapeutic use. Regulatory status varies internationally and should be verified with the relevant authority, as peptide regulations evolve. The compound falls under the WADA category S2 as a prohibited substance for competitive athletes.

References

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
3. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
4. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. doi:10.1016/j.ghir.2009.03.001
5. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.